Nap B.V. Forgrowth Sells 49,772 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 49,772 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $25.60, for a total value of $1,274,163.20. Following the completion of the sale, the insider now directly owns 10,802,224 shares of the company’s stock, valued at $276,536,934.40. This trade represents a 0.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.49, for a total value of $640,614.68.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Trading Down 1.4 %

Shares of NewAmsterdam Pharma stock opened at $25.86 on Friday. The business’s fifty day simple moving average is $21.99 and its 200 day simple moving average is $19.17. NewAmsterdam Pharma has a 12 month low of $10.50 and a 12 month high of $27.29.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma in the second quarter worth about $38,000. Quarry LP lifted its stake in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC grew its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG purchased a new stake in NewAmsterdam Pharma in the third quarter worth $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma in the third quarter valued at $187,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NAMS. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Scotiabank increased their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and a consensus target price of $36.20.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.